Baxter International, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Directors for upcoming cardiovascular device business spin-off in mid-2000 includes Michael Mussallem, who will be CEO and chairman of the new company. He has served as a group VP at Baxter since 1994. Also joining the board are Vernon Loucks, Baxter's current chairman, Avery Dennison Corp. President and CEO Philip Neal, and David Pyott, President and CEO of Allergan, Inc. The new company will have annual sales of approximately $900 mil
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.